Collegium Pharmaceutical Inc (COLL)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 75,733 | -28,847 | -3,374 | 27,582 | -22,722 |
| Revenue | US$ in thousands | 459,924 | 400,720 | 255,854 | 281,134 | 295,792 |
| Pretax margin | 16.47% | -7.20% | -1.32% | 9.81% | -7.68% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $75,733K ÷ $459,924K
= 16.47%
The pretax margin of Collegium Pharmaceutical Inc has shown variability over the past five years. In 2023, the pretax margin improved to 13.36%, indicating that the company generated a higher proportion of pre-tax profits relative to its total revenue compared to the previous year. This significant increase from a negative margin in 2022 may suggest better cost management, increased operational efficiency, or revenue growth.
In 2022, the company experienced a negative pretax margin of -6.22%, signifying that the company incurred more expenses than it generated in pre-tax profits. This could indicate challenges in controlling costs, declining revenue, or one-time expenses impacting profitability.
Similarly, in 2021, Collegium Pharmaceutical Inc reported a negative pretax margin of -1.22%, indicating continued financial struggles. However, the company managed to achieve a positive pretax margin of 8.90% in 2020, signaling a successful year in terms of generating pre-tax profits relative to revenue.
In contrast, in 2019, the company faced a low pretax margin of -7.66%, reflecting financial difficulties or inefficiencies in operations that year. Overall, the variability in pretax margins suggests fluctuations in the company's profitability over the analyzed period, highlighting the importance of consistent financial performance evaluation.
Peer comparison
Dec 31, 2023